SSTR5 and neuroendocrine carcinoma: Therefore, our results support interest in carrying out a clinical trial using pasireotide in the treatment of NET G3 and NEC as a new strategy to improve the therapeutic response of these tumors, previously histologically analyzing the presence of SSTR5 in candidate patients in a personalized approach.